A validated enantioselective LC-MS/MS assay for quantification of a major chiral metabolite of an achiral 11-β-hydroxysteroid-dehydrogenase 1 inhibitor in human plasma: Application to a clinical pharmacokinetic study.
BMS-823778 is a potent 11-β-hydroxysteroid-dehydrogenase 1 (11βHSD-1) inhibitor and a potential therapeutic agent for type 2 diabetes mellitus (T2DM). A high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay was developed and validated to enable reliable separation and quantification of both enantiomers of a chiral hydroxy metabolite (BMT-094817) in human plasma. Following liquid-liquid extraction in a 96-well plate format, chromatographic separation of the metabolite enantiomers was achieved by isocratic elution on a Chiralpak IA-3 column. Chromatographic conditions were optimized to ensure separation of both metabolite enantiomers. Metabolite enantiomers and stable isotope-labeled (SIL) internal standards were detected by positive ion electrospray tandem mass spectrometry. The LC-MS/MS assay was validated over a concentration range of 0.200-200ng/mL. Intra- and inter-assay precision values for replicate quality control samples were less than 9.9% for both enantiomers during the assay validation. Mean quality control accuracy values were within ±7.3%. Assay recoveries were high (>75%) and consistent across the assay range. The metabolite enantiomers were stable in human blood for 2h on ice. The analytes were also stable in human plasma for 25h at room temperature, 34days at -20°C and -70°C, and following five freeze-thaw cycles. No interconversion of the metabolite enantiomers was detected under any bioanalytical stress conditions, from blood collection/processing through extracted sample storage. The validated assay was successfully applied to the quantification of both metabolite enantiomers in human plasma in support of a human pharmacokinetic study.
Bristol-Myers Squibb, Research & Development, Analytical and Bioanalytical Development, Route 206 & Province Line Road, Princeton, NJ 08543, United States.
Michael T
MT
Furlong
Bristol-Myers Squibb, Research & Development, Analytical and Bioanalytical Development, Route 206 & Province Line Road, Princeton, NJ 08543, United States. Electronic address: Qin.Ji@bms.com.
Qin C
QC
Ji
Bristol-Myers Squibb, Research & Development, Exploratory Clinical & Translational Research, Route 206 & Province Line Road, Princeton, NJ 08543, United States.
Lisa
L
Iacono
Intertek Pharmaceutical Services, 10420 Wateridge Circle, San Diego, CA 92121, United States.
Oanh
O
Dang
Intertek Pharmaceutical Services, 10420 Wateridge Circle, San Diego, CA 92121, United States.
Marzena
M
Noren
Intertek Pharmaceutical Services, 10420 Wateridge Circle, San Diego, CA 92121, United States.
John
J
Bruce
Bristol-Myers Squibb, Research & Development, Analytical and Bioanalytical Development, Route 206 & Province Line Road, Princeton, NJ 08543, United States.
Anne-Françoise
AF
Aubry
Bristol-Myers Squibb, Research & Development, Analytical and Bioanalytical Development, Route 206 & Province Line Road, Princeton, NJ 08543, United States.
Mark E
ME
Arnold
D042842:11-beta-Hydroxysteroid Dehydrogenases / Q000037:antagonists & inhibitors*; D002853:Chromatography, Liquid / Q000379:methods*; D004791:Enzyme Inhibitors / Q000097:blood* / Q000737:chemistry / Q000493:pharmacokinetics; D006801:Humans; D015203:Reproducibility of Results; D013237:Stereoisomerism; D053719:Tandem Mass Spectrometry / Q000379:methods*
D004791:Enzyme Inhibitors; D042842:11-beta-Hydroxysteroid Dehydrogenases
11-β-Hydroxysteroid-dehydrogenase 1 inhibitor; Assay; Chiral separation; LC–MS/MS; Metabolite; Pharmacokinetics